Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
ZyVersa Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.40 | -$0.40 | -$0.40 |
| Q2 2025 | 1 | -$0.40 | -$0.40 | -$0.40 |
| Q3 2025 | 1 | -$0.25 | -$0.25 | -$0.25 |
| Q4 2025 | 1 | -$0.30 | -$0.30 | -$0.30 |
ZyVersa Therapeutics, Inc. Earnings Date And Information
ZyVersa Therapeutics, Inc. last posted its earnings results on Monday, May 12th, 2025. The company reported $-0.73 earnings per share for the quarter, missing analysts' consensus estimates of $-0.4 by $0.33. The company had revenue of 0 for the quarter and had revenue of 0 for the year. ZyVersa Therapeutics, Inc. has generated $-8 earnings per share over the last year ($-8.4803 diluted earnings per share) and currently has a price-to-earnings ratio of -0. ZyVersa Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 7th, 2025 based on prior year's report dates.
ZyVersa Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/12/2025 | Q1 2025 | -$0.40 | -$0.73 | -0.33 | $0 | $0 |
| 03/27/2025 | Q4 2024 | N/A | -$1.31 | N/A | $26.08 K | $0 |
| 11/14/2024 | Q3 2024 | -$5.80 | -$2.43 | 3.37 | $0 | $0 |
| 08/09/2024 | Q2 2024 | -$5.20 | -$3.31 | 1.89 | $0 | $0 |
| 05/15/2024 | Q1 2024 | -$3.70 | -$4.53 | -0.83 | N/A | $0 |
| 05/15/2024 | Q4 2023 | -$3.70 | -$32.92 | -29.22 | N/A | $15.60 K |
| 09/29/2023 | Q3 2023 | N/A | -$33.16 | N/A | N/A | $0 |
| 08/21/2023 | Q2 2023 | N/A | -$1,694.14 | N/A | N/A | $0 |
| 05/12/2023 | Q1 2023 | N/A | -$135.88 | N/A | N/A | $0 |
| 03/31/2023 | Q4 2022 | N/A | -$180.25 | N/A | N/A | $0 |
| 09/30/2022 | Q3 2022 | N/A | -$287.36 | N/A | N/A | $0 |
| 08/15/2022 | Q2 2022 | N/A | -$50.17 | N/A | N/A | $0 |
| 05/12/2022 | Q1 2022 | N/A | -$80.52 | N/A | N/A | $0 |
| 12/31/2021 | Q4 2021 | N/A | -$8.33 | N/A | N/A | $0 |
| 09/30/2021 | Q3 2021 | N/A | -$40.38 | N/A | N/A | $0 |
| 06/29/2021 | Q2 2021 | N/A | -$45.00 | N/A | N/A | $0 |
| 03/31/2021 | Q1 2021 | N/A | -$45.97 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
ZyVersa Therapeutics, Inc. Earnings: FAQ's
ZyVersa Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 7th, 2025 based offlast year's report dates.
The conference call for ZyVersa Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for ZyVersa Therapeutics, Inc.'s latest earnings report can be read online.
ZyVersa Therapeutics, Inc. (:ZVSA) has a recorded net income of $-9,413,435,000.ZyVersa Therapeutics, Inc. has generated $-8.4803 earnings per share over the last four quarters.
ZyVersa Therapeutics, Inc. (:ZVSA) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is -0.